On a positive note, the ST2/IL-33 pathway could represent a potential therapeutic target for controlling excessive pulmonary and systemic inflammation in patients with moderate to severe forms of COVID-19, by using anti-ST2 antibodies such as astegolimab [71,73]. Here, IL33 is linked to COVID-19.